HER2 Breast Cancer

Latest News

Depiction of hormone receptors | Image Credit: © DK_2020 - stock.adobe.com
Camizestrant Plus CDK 4/6 Inhibitor Improved PFS in Patients With HR+, HER2– Breast Cancer

March 5th 2025

Camizestrant is an investigational oral selective estrogen receptor degrader.

Breat cancer cells | Image Credit: © Thipphaphone - stock.adobe.com
Adding Bevacizumab to Vinorelbine, Platinum-Based Chemotherapy Improves Outcomes for Patients with HER2- Metastatic Breast Cancer

February 28th 2025

EGFR inhibited by targeted therapy | Image Credit: © patsuda - stock.adobe.com
Tanshinlactone May Inhibit the Growth of ER+, HER2+, or EGFR-Mutated Cells in Breast Cancer

February 24th 2025

New and Evolving: Pretreatment Risk Factors for Pneumonitis and Trastuzumab-Deruxtecan
New and Evolving: Pretreatment Risk Factors for Pneumonitis and Trastuzumab-Deruxtecan

February 20th 2025

Antibody drug conjugate molecules | Image Credit: © huenstructurebio.com - stock.adobe.com
Trastuzumab Deruxtecan Meets Primary End Point in the DEBBRAH Trial for Patients with HER2+ Advanced Breast Cancer

February 11th 2025

<123456